{"article_title": "Biosimilars Don't Deserve Unique Name, Group Tells FDA", "article_keywords": ["fda", "pharmaceutical", "group", "dont", "generic", "deserve", "biosimilars", "drug", "biologic", "york", "view", "unique", "tells", "names"], "article_url": "http://www.law360.com/articles/474602/biosimilars-don-t-deserve-unique-name-group-tells-fda", "article_text": "Biosimilars Don't Deserve Unique Name, Group Tells FDA\n\nLaw360, New York (September 20, 2013, 8:02 PM ET) -- A major generic pharmaceutical industry group told the U.S. Food and Drug Administration on Thursday not to give unique names to generic versions of biologic drugs, saying identical names for branded biologics and their biosimilars would not confuse customers or create drug safety concerns as some fear.\n\n\n\nFDA-approved biosimilars \u2014 copies of medicine derived from living cells \u2014 should share the same international nonproprietary name, or INN, as the biologic products to which they refer, according to a citizen petition filed by the Generic Pharmaceutical Association....\n\nTo view the full article, register now.", "article_metadata": {"description": "A major generic pharmaceutical industry group told the U.S. Food and Drug Administration on Thursday not to give unique names to generic versions of biologic drugs, saying identical names for branded biologics and their biosimilars would not confuse customers or create drug safety concerns as some fear.", "csrf-token": "taauGYW6ILqn6HK67thEeuNax93S/4oIRSbwZQKLm8dzvmRMTnaokEaCq4dEsgnBCQZRadChCbxG7I6mIlOhqA==", "og": {"url": "http://www.law360.com/articles/474602/biosimilars-don-t-deserve-unique-name-group-tells-fda", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Biosimilars Don't Deserve Unique Name, Group Tells FDA - Law360"}, "csrf-param": "authenticity_token", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/474602/biosimilars-don-t-deserve-unique-name-group-tells-fda", "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af36914bd0286fcf17d\"", "article_summary": "Biosimilars Don't Deserve Unique Name, Group Tells FDALaw360, New York (September 20, 2013, 8:02 PM ET) -- A major generic pharmaceutical industry group told the U.S. Food and Drug Administration on Thursday not to give unique names to generic versions of biologic drugs, saying identical names for branded biologics and their biosimilars would not confuse customers or create drug safety concerns as some fear.\nFDA-approved biosimilars \u2014 copies of medicine derived from living cells \u2014 should share the same international nonproprietary name, or INN, as the biologic products to which they refer, according to a citizen petition filed by the Generic Pharmaceutical Association....To view the full article, register now."}